Rapid Suppression of Plasma Testosterone Levels and Tumor Growth in the Dunning Rat Model Treated with Degarelix, a New Gonadotropin-Releasing Hormone Antagonist

@article{Princivalle2007RapidSO,
  title={Rapid Suppression of Plasma Testosterone Levels and Tumor Growth in the Dunning Rat Model Treated with Degarelix, a New Gonadotropin-Releasing Hormone Antagonist},
  author={M. Princivalle and P. Broqua and R. White and J. Meyer and G. Mayer and L. Elliott and K. Bjarnason and R. Haigh and C. Yea},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2007},
  volume={320},
  pages={1113 - 1118}
}
Degarelix (FE 200486) is a member of a new class of water-soluble (>50 mg/ml) gonadotropin-releasing hormone (GnRH) antagonists in clinical development for prostate cancer. Upon subcutaneous administration, degarelix forms a gel that results in a sustained release of the compound into the circulation, immediately blocking GnRH receptors in the pituitary and inducing a fast and sustained suppression of gonadotrophin secretion in rats and primates. One of the few animal models of prostate… Expand
51 Citations
Experience with degarelix in the treatment of prostate cancer
  • N. Shore
  • Medicine
  • Therapeutic advances in urology
  • 2013
  • 37
An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer
  • 40
  • PDF
Luteinising hormone-releasing hormone antagonists in prostate cancer therapy
  • 21
An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer
  • 45
Degarelix: A Review of Its Use in Patients with Prostate Cancer
  • 9
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
  • 115
  • Highly Influential
  • PDF
Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.
  • T. Redding, A. Schally
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1981
  • 132
  • PDF
Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists.
  • 25
Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
  • 14
  • PDF
Chronic effects of [D-Trp6-Pro9-NEt]luteinizing hormone-releasing factor on reproductive processes in the female rat.
  • 157
...
1
2
3
4
5
...